Clinical trials
Immune-related Adverse Event clinical trials
Below are recruiting immune-related adverse event clinical trials, each written for real people, not researchers. We’re tracking 29 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06337695RecruitingPhase 2/Phase 3
Preventing immunotherapy-related diarrhea in advanced cancer
This study tests whether vedolizumab, a drug that reduces gut inflammation, can prevent diarrhea caused by immunotherapy (a type of cancer treatment). It is for adults with advanced melanoma, lung, or kidney cancer who have a stool marker of inflammation early in treatment.
Calgary, AlbertaAges 18 years+ - NCT06860542RecruitingPhase 2
Inhaled steroid to prevent lung inflammation from returning after immunotherapy
This trial tests whether using an inhaled steroid (budesonide) can help prevent lung inflammation (pneumonitis) from coming back in people who have had it caused by immunotherapy cancer treatment. It may be an option for patients who need extra support after their first bout of this side effect.
Calgary, AlbertaAges 18 years+ - NCT06470971RecruitingPhase 2
Siltuximab to prevent severe side effects during immunotherapy rechallenge
This trial tests if siltuximab can prevent severe immune-related side effects when patients restart immunotherapy (anti-PD-1/PD-L1) after previous severe side effects. It aims to make rechallenge safer for people with advanced cancer.
Columbus, OhioAges 18 years+ - NCT05700565Recruiting
Treating hard-to-treat immune side effects after immunotherapy
This trial studies a treatment called ECP to help immune-related side effects (irAEs) that did not improve with standard steroid treatment. It may help control symptoms and change immune activity to reduce ongoing harm from immunotherapy.
MunichAges Any age - NCT05663775RecruitingPhase 2
Mesalamine to prevent bowel inflammation after melanoma immunotherapy
This study tests whether taking mesalamine can prevent colitis (bowel inflammation) in people with advanced melanoma who are treated with ipilimumab plus nivolumab. It may help reduce dangerous stomach or bowel side effects from this cancer treatment.
Edmonton, AlbertaAges 18 years+ - NCT06702566Recruiting
Study of Ferritin in Immune-Related Side Effects
This study looks at how a blood marker called ferritin relates to side effects from immunotherapy or other cancer treatments. It may help doctors predict and manage those side effects better.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT05832606Recruiting
Food changes to reduce side effects from immunotherapy
This trial tests whether a specific food plan can reduce side effects (toxicity) from standard immunotherapy that targets PD-1 and/or CTLA-4. It may help people tolerate treatment better while staying on their usual cancer care.
JetteAges 18 years+ - NCT07453342Recruiting
Safety of immunotherapy side effects and restarting treatment
This study looks at patients who had side effects from cancer immunotherapy (checkpoint inhibitors). The goal is to understand those side effects and whether it is safe to restart immunotherapy after they resolve.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07430579Recruiting
Adebrelimab with chemo for esophageal cancer
This trial tests adding adebrelimab (an immunotherapy drug) to standard chemotherapy for people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination helps shrink tumors before surgery.
JinanAges 18–80 - NCT05813418Recruiting
Finding blood and other clues for immune side effects
This study looks for early “predictive clues” (often blood or test markers) that can forecast immune-related side effects in people treated with immune checkpoint medicines. The goal is to help doctors recognize who may be more likely to have these side effects while receiving treatment.
Amiens, PicardieAges 18 years+ - NCT03989323Recruiting
Register to track cancer immune therapy and side effects
This study sets up a real-world patient database to follow people starting cancer immunotherapy and record immune-related side effects. You may help doctors better understand who gets these side effects and how they change over time.
BronAges 18 years+ - NCT04807127Recruiting
Testing blood and lung fluid markers for lung side effects
This study tries to find early warning markers in lung fluid collected during a bronchoscopy (a camera test of the airways). The goal is to better spot and understand lung inflammation that can happen after immune checkpoint cancer treatments.
Leuven, Flemish BrabantAges 18–120 - NCT05139706Recruiting
Study immune side effects after cancer immunotherapy
This study looks at how immune-related side effects happen in people treated with certain cancer immunotherapies. It also includes some healthy volunteers and people who already have similar autoimmune conditions, to better understand and compare these reactions.
Montreal, QuebecAges 18–100 - NCT05799898Recruiting
Fast heart and vessel check for people on immune cancer drugs
This trial looks at a faster heart and blood-vessel assessment for people who are taking immune cancer drugs and have been referred because they might be having a heart-related side effect. It may help by speeding up evaluation and treatment decisions when symptoms raise concern.
ParisAges 18 years+ - NCT06037811RecruitingPhase 2
Adalimumab for Immunotherapy-Related Arthritis
This study tests if a medicine called adalimumab (a type of TNF blocker) can help with new joint pain and swelling (inflammatory arthritis) caused by some immunotherapy drugs. It aims to reduce the need for high-dose steroids and improve symptoms.
London, OntarioAges 18 years+ - NCT06278857RecruitingPhase 2
Dostarlimab for early-stage MMR deficient endometrial cancer
This trial tests the drug dostarlimab for patients with early-stage endometrial cancer that is MMR deficient. It aims to see if the treatment is safe and effective for those who want to preserve their uterus or cannot have surgery.
Sydney, New South WalesAges 18 years+ - NCT06613165Recruiting
Short vs long treatment for stage II-III rectal cancer with dMMR
This trial tests how long you need a PD-1 immunotherapy before surgery for a specific type of rectal cancer (dMMR/MSI-H). It looks at whether a shorter or longer course works best. This could mean fewer side effects and a quicker path to surgery.
Xi'an, ShaanxiAges 18–80 - NCT06647134Recruiting
Understanding how immunotherapy side effects affect daily life
This study is for people whose immunotherapy (a type of cancer treatment) caused joint pain, swelling, or muscle stiffness. Researchers want to talk to you about how these side effects have affected your life, so they can better understand and help others in the future.
Houston, TexasAges 18 years+ - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06789601RecruitingPhase 1/Phase 2
Better tracking of immunotherapy side effects study
This trial aims to improve how doctors spot and track side effects from immunotherapy. If you are on or have had immunotherapy, your experience can help build a better system for monitoring these treatments.
Boston, MassachusettsAges Any age - NCT06841705RecruitingPhase 2
Early vedolizumab as first treatment for colitis from immunotherapy
This trial tests if giving vedolizumab early can help control severe diarrhea and colon inflammation caused by immunotherapy (a type of cancer treatment). It may offer a new option for people who develop these side effects.
Boston, MassachusettsAges 18 years+ - NCT07167251Recruiting
Low-dose steroids for immunotherapy-related liver inflammation
This trial tests whether using low-dose steroids can safely manage liver inflammation caused by immunotherapy. It may help patients who have moderate liver problems from their cancer treatment but haven't yet started high-dose steroids.
Basel, Canton of Basel-CityAges 18 years+ - NCT07249060Recruiting
Interferon levels in cancer and autoimmune disease patients
This study looks at a protein called interferon in the blood of people with cancer who are starting immunotherapy, and people with certain autoimmune diseases (such as lupus, Sjögren's syndrome, scleroderma, or inflammatory myopathy). The goal is to compare interferon patterns and better understand immune responses.
Pamplona, NavarreAges 18 years+ - NCT07357636Recruiting
Immune therapy side effects study for solid tumors
This study looks at side effects from immune checkpoint inhibitors in people with solid tumors. It aims to understand why side effects happen and who might be at risk, so doctors can better manage them.
Fuzhou, FujianAges 18 years+
Hear when a new Immune-related Adverse Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immune-related adverse event?
- Yes. Clin2 currently lists 29 recruiting immune-related adverse event studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune-related adverse event trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune-related adverse event trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.